CoChat

Mesenchymal stromal cell activation by breast cancer secretomes in bioengineered 3D microenvironments

Open access
Blache, Ulrich, Horton, Edward R, Xia, Tian, Schoof, Erwin M, Blicher, Lene H, Schönenberger, Angelina, Snedeker, Jess G, Martin, Ivan, Erler, Janine T, Ehrbar, Martin · 2019 · Life Science Alliance

The DOI matches its Crossref record; 85 of the 86 references it cites were found in a registry or an index.

Abstract

Mesenchymal stromal cells (MSCs) are key contributors of the tumour microenvironment and are known to promote cancer progression through reciprocal communication with cancer cells, but how they become activated is not fully understood. Here, we investigate how breast cancer cells from different stages of the metastatic cascade convert MSCs into tumour-associated MSCs (TA-MSCs) using unbiased, global approaches. Using mass spectrometry, we compared the secretomes of MCF-7 cells, invasive MDA-MB-231 cells, and sublines isolated from bone, lung, and brain metastases and identified ECM and exosome components associated with invasion and organ-specific metastasis. Next, we used synthetic hydrogels to investigate how these different secretomes activate MSCs in bioengineered 3D microenvironments. Using kinase activity profiling and RNA sequencing, we found that only MDA-MB-231 breast cancer secretomes convert MSCs into TA-MSCs, resulting in an immunomodulatory phenotype that was particularly prominent in response to bone-tropic cancer cells. We have investigated paracrine signalling from breast cancer cells to TA-MSCs in 3D, which may highlight new potential targets for anticancer therapy approaches aimed at targeting tumour stroma.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.26508/lsa.201900304

Cites

85 of 85 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1. Comparative proteomic analysis of breast cancer secretomes by mass spectrometry. (A) To cover a range of cancer progression steps, we used secretomes from noninvasive MCF-7 cells, invasive MDA-MB-231 cells (MDA-WT), and MDA-MB-231 sublines that were isolated from metastatic organs (the lung, bone, and brain). (B, C) The 10 most significantly overrepresented gene ontology terms for proteins that were significantly enriched (corrected P-value < 0.05) in secretomes of MCF-7 (B) or MDA-WT (C) are listed. (D) Subplot comparing matrisome proteins in the secretomes of MDA-WT and MCF-7 cells. (E) Hierarchical clustering analysis of significantly changed secretome proteins between MDA-WT and organ-tropic cells. Significantly changed proteins for each comparison are indicated by a black border. Quantitative heat map displays the level of enrichment between the MDA-WT (blue) and organ-tropic (red) secretomes. (F) Total protein gel (left) and Western blot analysis (right) of breast cancer secretomes. Band pixel intensities relative to MDA-WT are displayed. Proteins tested in Western blot analysis are highlight by an asterisk in (D, E). In (D, E), data are from three independent experiments and values represent the mean log2 fold change. Protein lysates used in (F) were pooled from three independent experiments. Source data are available for this figure.
Figure 1. Comparative proteomic analysis of breast cancer secretomes by mass spectrometry. (A) To cover a range of cancer progression steps, we used secretomes from noninvasive MCF-7 cells, invasive MDA-MB-231 cells (MDA-WT), and MDA-MB-231 sublines that were isolated from metastatic organs (the lung, bone, and brain). (B, C) The 10 most significantly overrepresented gene ontology terms for proteins that were significantly enriched (corrected P-value < 0.05) in secretomes of MCF-7 (B) or MDA-WT (C) are listed. (D) Subplot comparing matrisome proteins in the secretomes of MDA-WT and MCF-7 cells. (E) Hierarchical clustering analysis of significantly changed secretome proteins between MDA-WT and organ-tropic cells. Significantly changed proteins for each comparison are indicated by a black border. Quantitative heat map displays the level of enrichment between the MDA-WT (blue) and organ-tropic (red) secretomes. (F) Total protein gel (left) and Western blot analysis (right) of breast cancer secretomes. Band pixel intensities relative to MDA-WT are displayed. Proteins tested in Western blot analysis are highlight by an asterisk in (D, E). In (D, E), data are from three independent experiments and values represent the mean log2 fold change. Protein lysates used in (F) were pooled from three independent experiments. Source data are available for this figure.CC BY · PubMed Central
Figure S1. Proteins identified in MDA-WT and MCF-7 secretomes by LC-MS/MS. (A) Proteins identified in both MDA-WT and MCF-7 secretomes by LC-MS/MS are displayed in a volcano plot. (B) Exosome proteins are displayed in a volcano plot and the most significantly altered proteins are labeled by gene name. Data are from three independent experiments and values represent the mean log2 fold change (see Table S1).
Figure S1. Proteins identified in MDA-WT and MCF-7 secretomes by LC-MS/MS. (A) Proteins identified in both MDA-WT and MCF-7 secretomes by LC-MS/MS are displayed in a volcano plot. (B) Exosome proteins are displayed in a volcano plot and the most significantly altered proteins are labeled by gene name. Data are from three independent experiments and values represent the mean log2 fold change (see Table S1).CC BY · PubMed Central
Figure S2. Proteins identified uniquely in breast cancer secretomes by mass spectrometry. (A) Exosome proteins identified uniquely (see methods) in either MCF-7 or MDA-WT secretomes. (B) Matrisome proteins identified uniquely in either MDA-WT or MCF-7 secretomes. (C) Exosome (black text) or matrisome proteins identified uniquely in either MDA-WT or MDA-Bone secretomes. (D) Exosome (black text) or matrisome proteins identified uniquely in either MDA-WT or MDA-Lung secretomes. (E) Exosome (black text) or matrisome proteins identified uniquely in either MDA-WT or MDA-Brain secretomes. In (C–E), proteins depicted with an asterisk are both exosome and matrisome components.
Figure S2. Proteins identified uniquely in breast cancer secretomes by mass spectrometry. (A) Exosome proteins identified uniquely (see methods) in either MCF-7 or MDA-WT secretomes. (B) Matrisome proteins identified uniquely in either MDA-WT or MCF-7 secretomes. (C) Exosome (black text) or matrisome proteins identified uniquely in either MDA-WT or MDA-Bone secretomes. (D) Exosome (black text) or matrisome proteins identified uniquely in either MDA-WT or MDA-Lung secretomes. (E) Exosome (black text) or matrisome proteins identified uniquely in either MDA-WT or MDA-Brain secretomes. In (C–E), proteins depicted with an asterisk are both exosome and matrisome components.CC BY · PubMed Central
Figure 2. Bioengineered hydrogels and kinome profiles of MSC responses to breast cancer secretomes. (A) Schematic of biomimetic PEG hydrogels. Microscopy images show MSCs after 7 d of culture. Bight field image; scale bar: 100 μm. Representative immunofluorescence image of MSCs (F-actin cytoskeleton, red; nuclei, blue) and cell-derived ECM components (Perlecan, green). Image depicts Z-projections through 54 μm. Scale bar 20 μm. (B) MSCs were cultured in 3D hydrogels in the presence of secretomes from MCF-7, MDA-WT, or organ-tropic cells. MSCs were analysed by kinase profiling and RNA sequencing. (C) Volcano plot comparing phosphorylation levels of tyrosine peptides in MSCs treated with MDA-WT or MCF-7 secretomes. Values represent log2 intensity values, and the most significantly changed peptides are labeled by gene name and start-end residues of the peptide. (D) Comparative analysis of tyrosine kinase activity in MSCs treated with MDA-WT or MCF-7 secretomes. A relative measure of kinase activity (kinase statistic) is plotted against a combined score of significance and specificity for each kinase. (E) Hierarchical clustering analysis of tyrosine kinases in MSCs with altered activity in response to MDA-WT and organ-tropic secretomes. Kinases with highest score (>1), indicating altered kinase activity, are displayed with a black border. Quantitative heat map displays relative kinase activity (see Table S3). In all comparisons, data are from at least three independent experiments using different donor MSCs.
Figure 2. Bioengineered hydrogels and kinome profiles of MSC responses to breast cancer secretomes. (A) Schematic of biomimetic PEG hydrogels. Microscopy images show MSCs after 7 d of culture. Bight field image; scale bar: 100 μm. Representative immunofluorescence image of MSCs (F-actin cytoskeleton, red; nuclei, blue) and cell-derived ECM components (Perlecan, green). Image depicts Z-projections through 54 μm. Scale bar 20 μm. (B) MSCs were cultured in 3D hydrogels in the presence of secretomes from MCF-7, MDA-WT, or organ-tropic cells. MSCs were analysed by kinase profiling and RNA sequencing. (C) Volcano plot comparing phosphorylation levels of tyrosine peptides in MSCs treated with MDA-WT or MCF-7 secretomes. Values represent log2 intensity values, and the most significantly changed peptides are labeled by gene name and start-end residues of the peptide. (D) Comparative analysis of tyrosine kinase activity in MSCs treated with MDA-WT or MCF-7 secretomes. A relative measure of kinase activity (kinase statistic) is plotted against a combined score of significance and specificity for each kinase. (E) Hierarchical clustering analysis of tyrosine kinases in MSCs with altered activity in response to MDA-WT and organ-tropic secretomes. Kinases with highest score (>1), indicating altered kinase activity, are displayed with a black border. Quantitative heat map displays relative kinase activity (see Table S3). In all comparisons, data are from at least three independent experiments using different donor MSCs.CC BY · PubMed Central
Figure S3. Serine and threonine kinase profiles of MSC responses to breast cancer secretomes. (A) Volcano plot comparing phosphorylation levels of serine/threonine peptides in MSCs treated with MDA-WT or MCF-7 secretomes. Values represent log2 intensity values and the most significantly changed peptides are labeled by gene name and start–end residues of the peptide (Table S4). (B) Comparative analysis of serine/threonine kinase activity in MSCs treated with MDA-WT or MCF-7 secretomes. A relative measure of kinase activity (kinase statistic) is plotted against a combined score of significance and specificity for each kinase (Table S5). Kinases with highest score (>1), indicating altered kinase activity, are labeled by gene name. (C) Hierarchical clustering analysis of STKs in MSCs with altered activity in response to MDA-WT and organ-tropic secretomes. Kinases with highest score (>1), indicating altered kinase activity, are displayed with a black border. Quantitative heat map displays the relative kinase activity (see Table S5) in response to MDA-WT (blue) and organ-tropic (red) secretomes where colour is proportional to level of change. In all comparisons data are from four independent experiments using different donor MSCs.
Figure S3. Serine and threonine kinase profiles of MSC responses to breast cancer secretomes. (A) Volcano plot comparing phosphorylation levels of serine/threonine peptides in MSCs treated with MDA-WT or MCF-7 secretomes. Values represent log2 intensity values and the most significantly changed peptides are labeled by gene name and start–end residues of the peptide (Table S4). (B) Comparative analysis of serine/threonine kinase activity in MSCs treated with MDA-WT or MCF-7 secretomes. A relative measure of kinase activity (kinase statistic) is plotted against a combined score of significance and specificity for each kinase (Table S5). Kinases with highest score (>1), indicating altered kinase activity, are labeled by gene name. (C) Hierarchical clustering analysis of STKs in MSCs with altered activity in response to MDA-WT and organ-tropic secretomes. Kinases with highest score (>1), indicating altered kinase activity, are displayed with a black border. Quantitative heat map displays the relative kinase activity (see Table S5) in response to MDA-WT (blue) and organ-tropic (red) secretomes where colour is proportional to level of change. In all comparisons data are from four independent experiments using different donor MSCs.CC BY · PubMed Central
Figure S4. Phosphopeptide analysis of MSC responses to breast cancer secretomes. (A, B) Volcano plots comparing phosphorylation levels of tyrosine (A) and serine/threonine (B) peptides in MSCs treated with MDA-WT or MDA-organ secretomes. Values represent log2 intensity values and the most significantly changed peptides are labeled by gene name and start–end residues of the peptide (see Tables S2 and S4).
Figure S4. Phosphopeptide analysis of MSC responses to breast cancer secretomes. (A, B) Volcano plots comparing phosphorylation levels of tyrosine (A) and serine/threonine (B) peptides in MSCs treated with MDA-WT or MDA-organ secretomes. Values represent log2 intensity values and the most significantly changed peptides are labeled by gene name and start–end residues of the peptide (see Tables S2 and S4).CC BY · PubMed Central
Figure 3. Transcriptome profiles of MSC responses to breast cancer secretomes. Overrepresented Biological Process GO terms from genes that were significantly differentially expressed (P-value < 0.05) in MSCs upon treatment with the MDA-WT secretome compared with the MCF-7 secretome are displayed. Terms were hierarchically clustered, which identified clusters of genes associated with a similar set of functional terms. Selected clusters are labeled and a full list of terms is provided in Table S7. Relative expression is displayed as log2(MDA-WT/MCF-7) and colour is proportional to the level of gene expression change. Data represent the mean values from four independent experiments using different donor MSCs (see Table S6).
Figure 3. Transcriptome profiles of MSC responses to breast cancer secretomes. Overrepresented Biological Process GO terms from genes that were significantly differentially expressed (P-value < 0.05) in MSCs upon treatment with the MDA-WT secretome compared with the MCF-7 secretome are displayed. Terms were hierarchically clustered, which identified clusters of genes associated with a similar set of functional terms. Selected clusters are labeled and a full list of terms is provided in Table S7. Relative expression is displayed as log2(MDA-WT/MCF-7) and colour is proportional to the level of gene expression change. Data represent the mean values from four independent experiments using different donor MSCs (see Table S6).CC BY · PubMed Central
Figure 4. Additional analysis of transcriptome profiles of MSC responses to breast cancer secretomes. (A, B) Overrepresented Cellular Component (A) and Molecular Function (B) GO terms from genes that were significantly differentially expressed (P-value < 0.05) in MSCs upon treatment with the MDA-WT secretome compared with the MCF-7 secretome are displayed. Terms were hierarchically clustered, which identified clusters of genes associated with a similar set of functional terms. Relative expression is displayed as log2(MDA-WT/MCF-7) and colour is proportional to the level of gene expression change. (C–E) MA plots comparing transcriptome responses in MSCs treated with MDA-WT or organ-tropic secretomes (C, MDA-Bone; D, MDA-Lung; E, MDA-Brain). Significantly changed transcripts are indicated by red circles and are labeled with gene names. In all comparisons, data represent the mean values from four independent experiments using different donor MSCs (see Table S6).
Figure 4. Additional analysis of transcriptome profiles of MSC responses to breast cancer secretomes. (A, B) Overrepresented Cellular Component (A) and Molecular Function (B) GO terms from genes that were significantly differentially expressed (P-value < 0.05) in MSCs upon treatment with the MDA-WT secretome compared with the MCF-7 secretome are displayed. Terms were hierarchically clustered, which identified clusters of genes associated with a similar set of functional terms. Relative expression is displayed as log2(MDA-WT/MCF-7) and colour is proportional to the level of gene expression change. (C–E) MA plots comparing transcriptome responses in MSCs treated with MDA-WT or organ-tropic secretomes (C, MDA-Bone; D, MDA-Lung; E, MDA-Brain). Significantly changed transcripts are indicated by red circles and are labeled with gene names. In all comparisons, data represent the mean values from four independent experiments using different donor MSCs (see Table S6).CC BY · PubMed Central
Figure S5. Validation of gene expression changes in MSCs upon treatment with cancer secretomes. (A) Gene expression of chemokines and MMPs in MSCs treated with breast cancer secretomes (MCF-7 and MDA-WT). (B) Expression of genes that were differentially regulated between MDA-WT and MDA-Bone treated MSCs. (A, B) Gene expression was analysed by qRT–PCR and normalized to two reference genes (YWHAZ and HPRT1). Dashed line: untreated control. Bars show mean plus SD. Data are from four independent experiments using different donor MSCs (except for MMP8 where N = 3). *P < 0.05, **P < 0.01, ***P < 0.001, and ****P < 0.0001; t test. Source data are available for this figure.
Figure S5. Validation of gene expression changes in MSCs upon treatment with cancer secretomes. (A) Gene expression of chemokines and MMPs in MSCs treated with breast cancer secretomes (MCF-7 and MDA-WT). (B) Expression of genes that were differentially regulated between MDA-WT and MDA-Bone treated MSCs. (A, B) Gene expression was analysed by qRT–PCR and normalized to two reference genes (YWHAZ and HPRT1). Dashed line: untreated control. Bars show mean plus SD. Data are from four independent experiments using different donor MSCs (except for MMP8 where N = 3). *P < 0.05, **P < 0.01, ***P < 0.001, and ****P < 0.0001; t test. Source data are available for this figure.CC BY · PubMed Central
Figure 5. Network analysis, 3D migration, and immunomodulatory capacity of TA-MSCs. (A, B) Networks show matrisome proteins enriched in the MDA-WT secretome versus MCF-7 and kinases activated (A) or transcripts up-regulated (B) in MSCs by the MDA-WT secretome versus MCF-7. In both networks, node shape and colour corresponds to protein category as indicated and unconnected proteins are not shown. (C) Spheroid-based MSC migration experiments in PEG hydrogels. Z-stack projections of F-actin–stained MSC spheroids treated with breast cancer secretomes or PDGF-BB. Scale bar: 200 μm. Quantification of invaded area: Box plot shows the median (line), 25th and 75th percentiles (box), and min/max (whiskers). N = 12 spheroids from three independent experiments using three different donors. Individual data point for PDGF-BB. (D) Macrophage activation assay. Gene expression of macrophages treated with breast cancer secretomes (MCF-7, MDA-WT) or with secretomes collected from MSCs that were pretreated with breast cancer secretomes (MSC, MSCMCF-7, and MSCMDA-WT). Gene expression was analysed by qRT–PCR and normalized on two reference genes (GAPDH and ACTB). Dashed line: untreated control. Box plot shows the median (line), 25th and 75th percentiles (box), and min/max (whiskers). Data are from four independent experiments. *P < 0.05, **P < 0.01, ***P < 0.001, and ****P < 0.0001; t test. Source data are available for this figure.
Figure 5. Network analysis, 3D migration, and immunomodulatory capacity of TA-MSCs. (A, B) Networks show matrisome proteins enriched in the MDA-WT secretome versus MCF-7 and kinases activated (A) or transcripts up-regulated (B) in MSCs by the MDA-WT secretome versus MCF-7. In both networks, node shape and colour corresponds to protein category as indicated and unconnected proteins are not shown. (C) Spheroid-based MSC migration experiments in PEG hydrogels. Z-stack projections of F-actin–stained MSC spheroids treated with breast cancer secretomes or PDGF-BB. Scale bar: 200 μm. Quantification of invaded area: Box plot shows the median (line), 25th and 75th percentiles (box), and min/max (whiskers). N = 12 spheroids from three independent experiments using three different donors. Individual data point for PDGF-BB. (D) Macrophage activation assay. Gene expression of macrophages treated with breast cancer secretomes (MCF-7, MDA-WT) or with secretomes collected from MSCs that were pretreated with breast cancer secretomes (MSC, MSCMCF-7, and MSCMDA-WT). Gene expression was analysed by qRT–PCR and normalized on two reference genes (GAPDH and ACTB). Dashed line: untreated control. Box plot shows the median (line), 25th and 75th percentiles (box), and min/max (whiskers). Data are from four independent experiments. *P < 0.05, **P < 0.01, ***P < 0.001, and ****P < 0.0001; t test. Source data are available for this figure.CC BY · PubMed Central
Figure S6. Protein–protein interaction network models of MSC responses to breast cancer secretomes. (A) The network shows matrisome proteins enriched in the MDA-Bone secretome verses MDA-WT and kinases activated/transcripts up-regulated by the MDA-Bone secretome verses MDA-WT. (B) The network shows matrisome proteins enriched in the MDA-WT secretome verses MDA-Bone and kinases activated by the MDA-WT secretome verses MDA-Bone. In both networks, node shape and colour corresponds to protein category as indicated and unconnected proteins are not shown.
Figure S6. Protein–protein interaction network models of MSC responses to breast cancer secretomes. (A) The network shows matrisome proteins enriched in the MDA-Bone secretome verses MDA-WT and kinases activated/transcripts up-regulated by the MDA-Bone secretome verses MDA-WT. (B) The network shows matrisome proteins enriched in the MDA-WT secretome verses MDA-Bone and kinases activated by the MDA-WT secretome verses MDA-Bone. In both networks, node shape and colour corresponds to protein category as indicated and unconnected proteins are not shown.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

1 retracted

Show all 85 references

Cited by

Metadata

Authors
Blache, U., Horton, E. R., Xia, T., Schoof, E. M., Blicher, L. H., Schönenberger, A., Snedeker, J. G., Martin, I., Erler, J. T., & Ehrbar, M.
Affiliations
  • University of Zurich (CH)
  • University of Copenhagen (DK)
  • Technical University of Denmark (DK)
  • Institute for Biomechanics, Eidgenössische Technische Hochschule Zurich, Zurich, Switzerland
  • Department of Biomedicine, University Hospital Basel, University of Basel, Basel, Switzerland
Corresponding author
  • Erler, Janine T
  • Ehrbar, Martin
Venue
Life Science Alliance
Published
2019-06
Volume
2
Issue
3
Pages
e201900304
ISSN
2575-1077 (ISSN-L)
OpenAlex
W2948778357
Cited by
49
References
86
Citations by year
2026: 3 · 2024: 4 · 2023: 5 · 2022: 15 · 2021: 12 · 2020: 7 · 2019: 1
FWCI
4.81
Type
journal article
Language
en
Open access
Locations
  • Life Science Alliance (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • Research at the University of Copenhagen (University of Copenhagen) (publishedVersion, cc-by)
  • Zurich Open Repository and Archive (University of Zurich) (acceptedVersion, cc-by)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
  • Technical University of Denmark, DTU Orbit (Technical University of Denmark, DTU) (submittedVersion, cc-by)
  • Repository for Publications and Research Data (ETH Zurich) (submittedVersion, cc-by)
  • Zurich Open Repository and Archive (University of Zurich) (submittedVersion, cc-by)
  • ETH Zürich Research Collection (cc-by)
  • Zurich Open Repository and Archive (University of Zurich)
Funders
  • European Research Council (ERC-2015-CoG-682881-MATRICAN)
  • European Molecular Biology Organization (ATLF 922-2016)
  • Danish Cancer Society (R204-A12445)
  • European Union's Seventh Framework Programme (607868)
  • Swiss National Science Foundation (310030-169808/1)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Mesenchymal stem cell research
  • Health Sciences › Medicine › Oncology › Cancer Cells and Metastasis
  • Life Sciences › Immunology and Microbiology › Immunology › Immune cells in cancer
Keywords
mesenchymal stem cells, breast cancer, secretome, paracrine signaling, 3D microenvironment, synthetic hydrogels, exosomes, extracellular matrix, organ-specific metastasis, bone metastasis, immunomodulation, MDA-MB-231 cells, MCF-7 cells, tumor microenvironment, tumor stroma
MeSH terms
Breast Neoplasms, Chromatography, Liquid, Female, Humans, Mass Spectrometry, Tumor Cells, Cultured, Biomarkers, Cell Culture Techniques, Proteome, Gene Expression Profiling, Proteomics, Cell Line, Tumor, Metabolomics, Metabolome, Tumor Microenvironment, Mesenchymal Stem Cells

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.